Withdrawal of dopamine agonist treatment in patients with hyperprolactinaemia: A systematic review and meta-analysis.
dopamine agonists
hyperprolactinaemia
prolactinoma
Journal
Clinical endocrinology
ISSN: 1365-2265
Titre abrégé: Clin Endocrinol (Oxf)
Pays: England
ID NLM: 0346653
Informations de publication
Date de publication:
Nov 2022
Nov 2022
Historique:
revised:
18
01
2022
received:
03
11
2021
accepted:
16
02
2022
pubmed:
10
3
2022
medline:
6
10
2022
entrez:
9
3
2022
Statut:
ppublish
Résumé
To estimate the proportion of patients with persistent normoprolactinaemia following dopamine agonist (DA) withdrawal and to identify predictors of successful withdrawal in patients with hyperprolactinaemia. A systematic review of observational eligible studies were identified by searching PubMed and Embase. The primary outcome was the proportion of patients with normoprolactinaemia after cessation of DA treatment. Secondary outcome included the proportion of patients with normoprolactinaemia after DA withdrawal using individual patient data. Risk of bias was assessed by using Newcastle-Ottawa Scale. Pooled proportions were estimated using a random effects model in case I Thirty-two observational studies enroling 1563 patients were included. The proportion of patients with persistent normoprolactinaemia ranged from 0% to 75% (I The proportion of patients with persistent normoprolactinaemia following DA withdrawal treatment varied greatly, partly explained by the mean age of participants of the individual studies. Individual patient data analysis suggested that successful withdrawal was likely in patients with full regression of prolactinomas using a low maintenance dose before cessation.
Substances chimiques
Dopamine Agonists
0
Types de publication
Journal Article
Meta-Analysis
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
519-531Informations de copyright
© 2022 John Wiley & Sons Ltd.
Références
Casanueva FF, Molitch ME, Schlechte JA, et al. Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clin Endocrinol. 2006;65(2):265-273.
Colao A. Pituitary tumours: the prolactinoma. Best Pract Res Clin Endocrinol Metab. 2009;23(5):575-596.
Melmed S, Casanueva FF, Hoffman AR, et al. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(2):273-288.
Molitch ME. Diagnosis and treatment of pituitary adenomas: a review. JAMA. 2017;317(5):516-524.
Pereira AM. Update on the withdrawal of dopamine agonists in patients with hyperprolactinemia. Curr Opin Endocrinol, Diabetes Obes. 2011;18(4):264-268.
Romijn JA. Hyperprolactinemia and prolactinoma. In: Fliers E, Korbonits M, Romijn JA, eds. Handbook of Clinical Neurology. Vol 124. Elsevier; 2014:185-195.
Wang AT, Mullan RJ, Lane MA, et al. Treatment of hyperprolactinemia: a systematic review and meta-analysis. Syst Rev. 2012;1:33.
Chanson P, Maiter D. The epidemiology, diagnosis and treatment of prolactinomas: the old and the new. Best Pract Res Clin Endocrinol Metab. 2019;33(2):101290.
Beccuti G, Guaraldi F, Natta G, et al. Increased prevalence of impulse control disorder symptoms in endocrine diseases treated with dopamine agonists: a cross-sectional study. J Endocrinol Invest. 2021;44(8):1699-1706.
De Sousa SMC, Baranoff J, Rushworth RL, et al. Impulse control disorders in dopamine agonist-treated hyperprolactinemia: prevalence and risk factors. J Clin Endocrinol Metab. 2020;105:3.
Schade R, Andersohn F, Suissa S, Haverkamp W, Garbe E. Dopamine agonists and the risk of cardiac-valve regurgitation. N Eng J Med. 2007;356(1):29-38.
Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, Pezzoli G. Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N Eng J Med. 2007;356(1):39-46.
Herring N, Szmigielski C, Becher H, Karavitaki N, Wass JA. Valvular heart disease and the use of cabergoline for the treatment of prolactinoma. Clin Endocrinol. 2009;70(1):104-108.
Khare S, Lila A, Patil R, et al. Long-term cardiac (valvulopathy) safety of cabergoline in prolactinoma. Indian J Endocrinol Metab. 2017;21(1):154-159.
Drake WM, Stiles CE, Bevan JS, et al. A follow-up study of the prevalence of valvular heart abnormalities in hyperprolactinemic patients treated with cabergoline. J Clin Endocrinol Metab. 2016;101(11):4189-4194.
Dekkers OM, Lagro J, Burman P, Jørgensen JO, Romijn JA, Pereira AM. Recurrence of hyperprolactinemia after withdrawal of dopamine agonists: systematic review and meta-analysis. J Clin Endocrinol Metab. 2010;95(1):43-51.
Xia MY, Lou XH, Lin SJ, Wu ZB. Optimal timing of dopamine agonist withdrawal in patients with hyperprolactinemia: a systematic review and meta-analysis. Endocrine. 2018;59(1):50-61.
Hu J, Zheng X, Zhang W, Yang H. Current drug withdrawal strategy in prolactinoma patients treated with cabergoline: a systematic review and meta-analysis. Pituitary. 2015;18(5):745-751.
Ji MJ, Kim JH, Lee JH, et al. Best candidates for dopamine agonist withdrawal in patients with prolactinomas. Pituitary. 2017;20(5):578-584.
Teixeira M, Souteiro P, Carvalho D. Prolactinoma management: predictors of remission and recurrence after dopamine agonists withdrawal. Pituitary. 2017;20(4):464-470.
Watanabe S, Akutsu H, Takano S, et al. Long-term results of cabergoline therapy for macroprolactinomas and analyses of factors associated with remission after withdrawal. Clin Endocrinol. 2017;86(2):207-213.
Santharam S, Fountas A, Tampourlou M, et al. Impact of menopause on outcomes in prolactinomas after dopamine agonist treatment withdrawal. Clin Endocrinol. 2018;89(3):346-353.
Indirli R, Ferrante E, Sala E, Giavoli C, Mantovani G, Arosio M. Cabergoline withdrawal before and after menopause: outcomes in microprolactinomas. Hormones & cancer. 2019;10(2-3):120-127.
Espinosa-Cárdenas E, Sánchez-García M, Ramírez-Rentería C, Mendoza-Zubieta V, Sosa-Eroza E, Mercado M. High biochemical recurrence rate after withdrawal of cabergoline in prolactinomas: is it necessary to restart treatment? Endocrine. 2020;70(1):143-149.
Hage C, Salvatori R. Predictors of the response to dopaminergic therapy in patients with prolactinoma. J Clin Endocrinol Metab. 2020;105(12):4558-4566.
Kim K, Park YW, Kim D, et al. Biochemical remission after cabergoline withdrawal in hyperprolactinemic patients with visible remnant pituitary adenoma. J Clin Endocrinol Metab. 2020
Stewart GB, Altman DG, Askie LM, Duley L, Simmonds MC, Stewart LA. Statistical analysis of individual participant data meta-analyses: a comparison of methods and recommendations for practice. PLoS One. 2012;7(10):e46042.
Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol. 2014;14:135.
Borenstein M, Hedges L, Higgins J, Rothstein H. Comprehensive meta-analysis [computer program]. Version 3. Biostat; 2013.
Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539-1558.
Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557-560.
RStudio. Integrated development environment for R [computer program]. RStudio Team; 2016.
Anagnostis P, Adamidou F, Polyzos SA, Efstathiadou Z, Karathanassi E, Kita M. Long term follow-up of patients with prolactinomas and outcome of dopamine agonist withdrawal: a single center experience. Pituitary. 2012;15(1):25-29.
Barber TM, Kenkre J, Garnett C, Scott RV, Byrne JV, Wass JAH. Recurrence of hyperprolactinaemia following discontinuation of dopamine agonist therapy in patients with prolactinoma occurs commonly especially in macroprolactinoma. Clin Endocrinol. 2011;75(6):819-824.
Biswas M, Smith J, Jadon D, et al. Long-term remission following withdrawal of dopamine agonist therapy in subjects with microprolactinomas. Clin Endocrinol. 2005;63(1):26-31.
Cannavò S, Curtò L, Squadrito S, Almoto B, Vieni A, Trimarchi F. Cabergoline: a first-choice treatment in patients with previously untreated prolactin-secreting pituitary adenoma. J Endocrinol Invest. 1999;22(5):354-359.
Coculescu M, Simionescu N, Oprescu M, Alessandrescu D. Bromocriptine treatment of pituitary adenomas. Evaluation of withdrawal effect. Endocrinologie. 1983;21(3):157-168.
Colao A, Di Sarno A, Cappabianca P, Di Somma C, Pivonello R, Lombardi G. Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia. N Eng J Med. 2003;349(21):2023-2033.
Colao A, Di Sarno A, Guerra E, et al. Predictors of remission of hyperprolactinaemia after long-term withdrawal of cabergoline therapy. Clin Endocrinol. 2007;67(3):426-433.
Dogansen SC, Selcukbiricik OS, Tanrikulu S, Yarman S. Withdrawal of dopamine agonist therapy in prolactinomas: in which patients and when? Pituitary. 2016;19(3):303-310.
Eversmann T, Fahlbusch R, Rjosk HK, Von Werder K. Persisting suppression of prolactin secretion after long-term treatment with bromocriptine in patients with prolactinomas. Acta Endocrinol. 1979;92(3):413-427.
Ferrari C, Paracchi A, Mattei AM, De Vincentiis S, D'Alberton A, Crosignani P. Cabergoline in the long-term therapy of hyperprolactinemic disorders. Acta Endocrinol. 1992;126(6):489-494.
Guitelman M. Long-term follow-up of prolactinomas: should dopamine agonist treatment be life-long? Front Horm Res. 2006;35:88-101.
Ho KY, Smythe GA, Compton PJ, Lazarus L. Long-term bromocriptine therapy may restore the inhibitory control of prolactin release in some patients with pathological hyperprolactinemia. Aust N Z J Med. 1985;15(2):213-219.
Huda MS, Athauda NB, Teh MM, Carroll PV, Powrie JK. Factors determining the remission of microprolactinomas after dopamine agonist withdrawal. Clin Endocrinol. 2010;72(4):507-511.
Kharlip J, Salvatori R, Yenokyan G, Wand GS. Recurrence of hyperprolactinemia after withdrawal of long-term cabergoline therapy. J Clin Endocrinol Metab. 2009;94(7):2428-2436.
Kwancharoen R, Auriemma RS, Yenokyan G, Wand GS, Colao A, Salvatori R. Second attempt to withdraw cabergoline in prolactinomas: a pilot study. Pituitary. 2014;17(5):451-456.
Mattei AM, Ferrari C, Ragni G, et al. Serum prolactin and ovarian function after discontinuation of drug treatment for hyperprolactinaemia: a study with bromocriptine and metergoline. Br J Obstet Gynaecol. 1984;91(3):244-250.
Maxson WS, Dudzinski M, Handwerger SH, Hammond CB. Hyperprolactinemic response after bromocriptine withdrawal in women with prolactin-secreting pituitary tumors. Fertil Steril. 1984;41(2):218-223.
Moriondo P, Travaglini P, Nissim M, Conti A, Faglia G. Bromocriptine treatment of microprolactinomas: evidence of stable prolactin decrease after drug withdrawal. J Clin Endocrinol Metab. 1985;60(4):764-772.
Muratori M, Arosio M, Gambino G, Romano C, Biella O, Faglia G. Use of cabergoline in the long-term treatment of hyperprolactinemic and acromegalic patients. J Endocrinol Invest. 1997;20(9):537-546.
Passos VQ, Souza JJS, Musolino NRC, Bronstein MD. Long-term follow-up of prolactinomas: Normoprolactinemia after bromocriptine withdrawal. J Clin Endocrinol Metab. 2002;87(8):3578-3582.
Sala E, Bellaviti Buttoni P, Malchiodi E, et al. Recurrence of hyperprolactinemia following dopamine agonist withdrawal and possible predictive factors of recurrence in prolactinomas. J Endocrinol Invest. 2016;39(12):1377-1382.
Sobrinho LG, Nunes MC, Calhaz-Jorge C. Effect of treatment with bromocriptine on the size and activity of prolactin producing pituitary tumours. Acta Endocrinol. 1981;96(1):24-29.
Van't Verlaat JW, Croughs RJM. Withdrawal of bromocriptine after long-term therapy for macroprolactinomas; effect on plasma prolactin and tumour size. Clin Endocrinol. 1991;34(3):175-178.
Vilar L, Albuquerque JL, Gadelha PS, et al. Second attempt of cabergoline withdrawal in patients with prolactinomas after a failed first attempt: is it worthwhile? Front Endocrinol. 2015;6:11.
Zárate A, Canales ES, Cano C, Pilonieta CJ. Follow-up of patients with prolactinomas after discontinuation of long-term therapy with bromocriptine. Acta Endocrinol. 1983;104(2):139-142.
Cochrane Training. Cochrane handbook for systematic reviews of interventions. https://training.cochrane.org/handbook/current
Rücker G, Schwarzer G, Carpenter JR, Schumacher M. Undue reliance on I(2) in assessing heterogeneity may mislead. BMC Med Res Methodol. 2008;8:79.